Table 2.
IEL | Hp- dyspeptic patients (n = 20) Median % (range %) | Hp+ dyspeptic patients (n = 6) Median % (range %) | Healthy control adults (n = 12) Median % (range %) | P |
CD3+ | 93 (80-98) | 94.5 (89-99) | 96 (84-99) | aceP > 0.5 |
CD3+ CD4+ | 8 (3-34) | 8 (3-15) | 10 (2-22) | aceP > 0.5 |
CD3+ CD8+ | 78 (58-96) | 86 (75-87) | 77 (53-87) | acP > 0.5 |
bP < 0.01 | ||||
CD3+ TCRgd+ | 22 (1-36) | 10 (10-30) | 24 (8-60) | aceP > 0.5 |
CD3+ CD103+ | 91 (58-96) | 81 (75-87) | 90 (80-99) | aceP > 0.5 |
CD3+ CD44+ | 95 (50-99) | 94 (84-100) | 94 (65-100) | aceP > 0.5 |
CD3+ CD28+ | 2 (1-11) | 5 (1-10) | 7 (1-9) | aceP > 0.5 |
CD3+ CD69+ | 97 (68-100) | 99 (96-100) | 96 (91-98) | aceP > 0.5 |
P > 0.5, Hp- vs control;
P > 0.5, Hp- vs Hp+;
P > 0.5, Hp+ vs control;
P < 0.01, Hp+ vs control.